← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Pharmatrophix, Inc.
Menlo Park, CA
$7,299,048
Total funding
1
Grants
Funding over time
peak $2.8M · FY2016–19$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
Funding mix
By agency
NIH$7,299,048 · 1
By mechanism
R01$7,299,048 · 1
Investigators at Pharmatrophix, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.$2,559,183
R01 · FY2019 · AG
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.$1,499,874
R01 · FY2016 · AG
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.$1,499,544
R01 · FY2017 · AG
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.$1,495,447
R01 · FY2018 · AG
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.$245,000
R01 · FY2019 · AG